Literature DB >> 12709297

Nicotinamide protects HCN2 cells from the free radical generating toxin, tertiary butylhydroperoxide (t-BuOOH).

Manisha Sonee1, Johanna R. Martens, Suman K. Mukherjee.   

Abstract

In previous studies with mice the oxygen radical generating neurotoxin tertiary butylhydroperoxide (t-BuOOH) was used to mimic the oxidative injury that has been implicated in neurodegenerative diseases. In addition, previous studies have shown that the poly (ADP-ribose) polymerase (PARP) inhibitor nicotinamide is able to prevent DNA fragmentation and apoptosis that is induced by t-BuOOH in mouse brain. However, the molecular mechanism(s) by which nicotinamide is able to protect human brain cells at the cellular level is not clear. Therefore in this study a cell culture model system with human cortical neuronal cells (HCN2 cells) has been employed where the molecular mechanism(s) of nicotinamide action, both in the presence and absence of t-BuOOH has been studied. Human cortical neurons (HCN2 cells) have been shown to differentiate to a neuron-like morphology. In this study, exposure of HCN2 cells to t-BuOOH resulted in altered morphology and disruption of neuronal differentiation leading to cell death. However, in neurons, which were treated with nicotinamide before being exposed to t-BuOOH, neuronal differentiation was preserved; morphological disruption was prevented and cell death was reduced significantly. Moreover, our studies indicate that nicotinamide is able to prevent the up-regulation of the pro-apoptotic proteins p53 and p21/WAF-1, and the down-regulation of the anti-apoptotic protein bcl-2 that is induced by t-BuOOH in HCN2 cells. Thus this study indicates that nicotinamide protects human brain cells from the toxic effects of free radical generating toxins by regulating the levels of various pro- and anti-apoptotic proteins.

Entities:  

Year:  2002        PMID: 12709297     DOI: 10.1080/1029842021000045480

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  16 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Ca(2+)-calmodulin antagonist chlorpromazine and poly(ADP-ribose) polymerase modulators 4-aminobenzamide and nicotinamide influence hepatic expression of BCL-XL and P53 and protect against acetaminophen-induced programmed and unprogrammed cell death in mice.

Authors:  S D Ray; G Balasubramanian; D Bagchi; C S Reddy
Journal:  Free Radic Biol Med       Date:  2001-08-01       Impact factor: 7.376

Review 3.  p53: DNA damage, DNA repair, and apoptosis.

Authors:  C Götz; M Montenarh
Journal:  Rev Physiol Biochem Pharmacol       Date:  1996       Impact factor: 5.545

4.  Poly(ADP-ribosyl)ation of p53 during apoptosis in human osteosarcoma cells.

Authors:  C M Simbulan-Rosenthal; D S Rosenthal; R Luo; M E Smulson
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

5.  The effects of aging and neurodegeneration on apoptosis-associated DNA fragmentation and the benefits of nicotinamide.

Authors:  S K Mukherjee; J D Adams
Journal:  Mol Chem Neuropathol       Date:  1997 Sep-Dec

6.  Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease.

Authors:  S Love; R Barber; G K Wilcock
Journal:  Brain       Date:  1999-02       Impact factor: 13.501

7.  Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.

Authors:  M Endres; Z Q Wang; S Namura; C Waeber; M A Moskowitz
Journal:  J Cereb Blood Flow Metab       Date:  1997-11       Impact factor: 6.200

8.  Oxidative changes in brain pyridine nucleotides and neuroprotection using nicotinamide.

Authors:  L K Klaidman; S K Mukherjee; J D Adams
Journal:  Biochim Biophys Acta       Date:  2001-02-16

9.  Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.

Authors:  S Martin-Aragon; S K Mukherjee; B J Taylor; S P Ivy; C H Fu; V C Ardi; V I Avramis
Journal:  Anticancer Res       Date:  2000 Jan-Feb       Impact factor: 2.480

10.  A human temperature-sensitive p53 mutant p53Val-138: modulation of the cell cycle, viability and expression of p53-responsive genes.

Authors:  K Yamato; M Yamamoto; Y Hirano; N Tsuchida
Journal:  Oncogene       Date:  1995-07-06       Impact factor: 9.867

View more
  3 in total

1.  Nicotinamide induces apoptosis of F9 mouse teratocarcinoma stem cells by downregulation of SATB1 expression.

Authors:  Yan Zhang; Haibo Wu; Man Zhang; Yali Jiang; Weiwei Zhuo; Yong Zhang; Song Hua
Journal:  Tumour Biol       Date:  2015-01-17

Review 2.  Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.

Authors:  Seon Beom Song; Jin Sung Park; Gu June Chung; In Hye Lee; Eun Seong Hwang
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

3.  Use of Metabolomics to Trend Recovery and Therapy After Injury in Critically Ill Trauma Patients.

Authors:  Brodie A Parent; Max Seaton; Ravi F Sood; Haiwei Gu; Danijel Djukovic; Daniel Raftery; Grant E O'Keefe
Journal:  JAMA Surg       Date:  2016-07-20       Impact factor: 14.766

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.